Results 41 to 50 of about 2,551 (122)

Research Progress of Berberine in Kidney Disease: Targeting Mitochondria and Ferroptosis

iNew Medicine, EarlyView.
This figure illustrates the model‐specific renoprotective mechanisms of berberine (BBR) across three major kidney diseases. From left to right, the diagram shows that BBR targets distinct core pathways depending on the pathological context: in diabetic nephropathy (DN), BBR activates AMPK to improve mitochondrial energy metabolism; in acute kidney ...
Liuqing Wang, Rongyu Guo, Xiaojun Feng, Liqin Tang   +3 more
wiley   +1 more source

Development and Validation of a Spectrophotometric Method for Quantification and Dissolution Studies of Glimepiride in Tablets

E-Journal of Chemistry, 2012
The objective of present study was to develop and validate an analytical method for quantitative determination and dissolution studies of glimepiride in tablets. The glimepiride shows absorption maxima at 225 nm and obeyed Beer's law in the range of 6.0 –
Madhusudhanareddy Induri, Bhagavan Raju M., Rajendra Prasad Y., Pavankumar Reddy K.   +3 more
doaj   +1 more source

Development and validation of liquid chromatography method for determination of glimepiride in presence of (Vimto®) soft drinks in rats: application to pharmacokinetics studies

Journal of Pharmacy and Bioallied Sciences, 2019
Context: Diet and beverages are thought to have notable effects on drugs. Recently, this relationship has received significant consideration. Aims: To develop and validate a simple, rapid, and sensitive method for the determination of glimepiride in rat ...
Mohammed Hamad, Areej Rahhal, Wael Abu Dayyih, Eyad Mallah, Alice Abu Dayyih, Zainab Zakaria, Tawfiq Arafat   +6 more
doaj   +1 more source

Clinical Utility of Glimepiride and Metformin Fixed-Dose Combination in Obese/Overweight Patients with Type 2 Diabetes Mellitus in Indian Settings

Chronicle of Diabetes Research and Practice, 2022
Background: In India, glimepiride has become a promising option for add-on therapy with metformin in patients with type-2 diabetes mellitus (T2DM) owing to its efficacy, safety, and cost-effectiveness.
Binayak Sinha, Saket Kant, Sabyasachi Bandyopadhyay, Sagarika Mukherjee, Dasarathi Sarkar, Kiran P. Singh, Tirthankar Chaudhury, Surender Kumar, Rahimuddin Ahmed, Mahesh Abhyankar, Ashish Prasad, Mayuri Talathi   +11 more
doaj   +1 more source

Gymnema sylvestre: Bioactive constituents, health benefits, and emerging applications in nutraceuticals and functional foods

JSFA reports, EarlyView.
Abstract Gymnema sylvestre (Retz.) R.Br. ex‐Schult., commonly known as “gurmar” or “sugar destroyer,” belongs to the Apocynaceae family and is traditionally used in Ayurveda for diabetes management. This review synthesizes ethnomedicinal evidence with contemporary pharmacological studies, to evaluate the therapeutic properties and mechanistic actions ...
Faiza Saeed, Muhammad Tauseef Sultan, Hassan Raza, Ahmad Mujtaba Noman, Nimra Haroon, Entessar Mohammad Al Jbawi   +5 more
wiley   +1 more source

Magnetothermal‐responsive drug release bone cement based on EGFR‐mutated lung cancer bone metastases

VIEW, EarlyView.
A novel magnetothermal‐responsive bone cement was developed by integrating PMMA/CPC/Osimertinib matrix with Fe3O4@SiO2@Zol nanomaterials. This dual‐drug system achieves controlled release, combining excellent mechanical properties with potent anti‐tumor activity and bone regulation for treating EGFR‐mutated LC‐BoM.
Kandi Xu, Kai Li, Hao Wang, Lishu Zhao, Xinyue Liu, Yujin Liu, Li Ye, Wengang Zhang, Zhimin Chen, Xuyang Chen, Yujie Li, Qianqian Zhang, Wencheng Zhao, Xuebin Zheng, Yu Chen, Yayi He   +15 more
wiley   +1 more source

Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg, R. Kitchen, R. Gupta, L. Donnelly, E. R. Pearson   +4 more
wiley   +1 more source

Modern antihyperglycemic therapy: safety and efficacy of glimepiride [PDF]

, 2012
Current review analyzes pharmacological and clinical aspects of glimepiride from perspective of the evidence-based medicine. We aimedto determine position of glimepiride within modern antihyperglycemic dialectics of safety and efficacy.
Maksim Yur'evich Sorokin, Lyudmila Alexandrovna Ruyatkina   +1 more
core   +1 more source

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

European Journal of Haematology, EarlyView.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha, Brian A. Walker, Pengyue Zhang   +6 more
wiley   +1 more source

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

The Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet, Rosie Nucci, Jacqueline L. Beaudry   +2 more
wiley   +1 more source